Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1
Johannes Grimm, Anita Hufnagel, Marion Wobser, et al.
Oncogenesis (2018) Vol. 7, Iss. 9
Open Access | Times Cited: 20

Showing 20 citing articles:

Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 225
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Aphrothiti J. Hanrahan, Ziyu Chen, Neal Rosen, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 224-247
Closed Access | Times Cited: 42
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
Jakub Szymczyk, Katarzyna Dominika Sluzalska, Izabela Materla, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5796-5796
Open Access | Times Cited: 61
Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma
Rasha M. Allam, Ahmed M. El Kerdawy, Ahmed Gouda, et al.
Bioorganic Chemistry (2024) Vol. 146, pp. 107243-107243
Closed Access | Times Cited: 14
Expression and function of FRA1 protein in tumors
Xiao‐Yan Jiang, Hui Xie, Yingyu Dou, et al.
Molecular Biology Reports (2019) Vol. 47, Iss. 1, pp. 737-752
Closed Access | Times Cited: 69
Fibroblast Growth Factor Receptor Signaling in Skin Cancers
Małgorzata Czyż
Cells (2019) Vol. 8, Iss. 6, pp. 540-540
Open Access | Times Cited: 59
The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications’ door
Francesco Talotta, Laura Casalino, Pasquale Verde
Oncogene (2020) Vol. 39, Iss. 23, pp. 4491-4506
Closed Access | Times Cited: 57
A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
Yangzi Tian, Weinan Guo
Medical Science Monitor (2020) Vol. 26
Open Access | Times Cited: 56
Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma
Ahmad Najem, Laura Soumoy, Malak Sabbah, et al.
Cells (2022) Vol. 11, Iss. 7, pp. 1157-1157
Open Access | Times Cited: 23
Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers
Bernhard Biersack, Lubna H. Tahtamouni, Michael Höpfner
Receptors (2024) Vol. 3, Iss. 1, pp. 58-106
Open Access | Times Cited: 4
Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition
Florencia P. Madorsky Rowdo, Antonela Bar�n, Stuart J. Gallagher, et al.
International Journal of Oncology (2020)
Open Access | Times Cited: 25
The Potent and Paradoxical Biology of Cellular Senescence in Cancer
Paul B. Romesser, Scott W. Lowe
Annual Review of Cancer Biology (2023) Vol. 7, Iss. 1, pp. 207-228
Open Access | Times Cited: 7
Aspirin–Fisetin Combinatorial Treatment Exerts Cytotoxic and Anti-Migratory Activities in A375 Malignant Melanoma Cells
Claudia Iftode, Daliana Minda, George Drăghici, et al.
Medicina (2024) Vol. 60, Iss. 7, pp. 1125-1125
Open Access | Times Cited: 2
Phenotypic plasticity of melanocytes derived from human adult skin
Dániel László Vidács, Zoltán Veréb, Renáta Bozó, et al.
Pigment Cell & Melanoma Research (2021) Vol. 35, Iss. 1, pp. 38-51
Open Access | Times Cited: 13
A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity
Carmela Gallo, Giusi Barra, Marisa Saponaro, et al.
Marine Drugs (2020) Vol. 18, Iss. 12, pp. 604-604
Open Access | Times Cited: 12
Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
Baptiste Louveau, Fanélie Jouenne, Coralie Reger de Moura, et al.
Cancers (2019) Vol. 11, Iss. 8, pp. 1203-1203
Open Access | Times Cited: 10
A Transient Metabolic State In Melanoma Persister Cells Mediated By Chemotherapeutic Treatments
Prashant Karki, Vahideh Angardi, Juan C. Mier, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 7
<p>Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells</p>
Marta Osrodek, Michał Różański, Małgorzata Czyż
Cancer Management and Research (2020) Vol. Volume 12, pp. 7231-7250
Open Access | Times Cited: 4
Quercetin Enhances 5-Fluorouracil-Driven Cytotoxicity Dose-Dependently in A375 Human Melanoma Cells
Andrea Roman, Andreea Smeu, Ana Lascu, et al.
Life (2024) Vol. 14, Iss. 12, pp. 1685-1685
Open Access
Melanoma
Marcella Occelli, Anna Maria Vandone, Carolina Cauchi, et al.
Anti-Cancer Drugs (2019) Vol. 30, Iss. 6, pp. 543-553
Closed Access | Times Cited: 1
Page 1

Scroll to top